肾移植失功患者左心室功能状态及其影响因素
|
摘要
[目的]
评价肾移植失功患者左心室功能状态及其影响因素。
[方法]
选取肾移植失功血透患者为肾移植失功组,未行肾移植的终末期肾病患者为初发血透组,比较两组初次血透前左室结构及功能指标,同时比较两组血化验指标。
[结果]
肾移植失功组IVSd、IVSs、LVPWd、LVPWs较初发血透组显著增厚(P<0.01)；肾移植失功组LVMI较初发血透组显著增加(P<0.01)；肾移植失功组Hb、Alb、 Pre-Alb、TRF水平显著低于初发血透组(P<0.05)；肾移植失功组Cr、BUN水平较初发血透组低(P<0.05),GFR较初发血透组高(P<0.01)；肾移植失功组CRP水平较初发血透组高(P<0.01)；其余指标均无显著性差异(P>0.05)。
[结论]
肾移植失功组左室重塑较初发血透组显著,其微炎症状态、贫血、营养不良程度也更显著。肾移植失功患者长期使用免疫抑制剂,加重贫血、营养不良及微炎症状态,增加肾移植患者心血管疾病的风险。肾移植患者出现肾功能不全时需要及早的干预治疗。肾移植状态存在多种因素影响患者的心脏结构和功能,因此,早期监测、预防及治疗对肾移植患者减少心血管并发症具有重要意义。
[Objective]
To study left ventricular function and its influence factors in renal transplant patients through graft loss.
[Methods]
The case group is renal transplant patients through graft loss, the control group is the patients with end-stage kidney disease but without renal transplant. Left ventricular structure and function indexs were measured by color doppler echocardiography. The blood assay indexs were determined.
[Results]
The level of IVSd, IVSs, LVPWd, LVPWs in case group were obviously higher than the control group (P<0.01);and the LVMI of the case group was higher (P<0.01); the level of Alb, Hb, Pre-Alb, TRF were obviously lower than those in control (P<0.05); The level of Cr, BUN increased in control group (P<0.05), and GFR reduced (P <0.01); The level of CRP was elevated in case group (P<0.01); The rest of the indexs had no significant difference (P>0.05).
[Conclusion]
The left ventricular remodeling of graft loss patients is significantly higher than the control group, and the micro inflammation state, anemia, malnutrition are more serious. Immune inhibitors increase micro inflammation state, anemia, and malnutrition, which increase the risk of cardiovascular disease. Early intervention treatment is needed when graft loss patients appear renal insufficiency. Various factors will influence the cardio structure and function of renal transplant patients. Therefore, early detection, prevention and treatment are important.
评价肾移植失功患者左心室功能状态及其影响因素。
[方法]
选取肾移植失功血透患者为肾移植失功组,未行肾移植的终末期肾病患者为初发血透组,比较两组初次血透前左室结构及功能指标,同时比较两组血化验指标。
[结果]
肾移植失功组IVSd、IVSs、LVPWd、LVPWs较初发血透组显著增厚(P<0.01)；肾移植失功组LVMI较初发血透组显著增加(P<0.01)；肾移植失功组Hb、Alb、 Pre-Alb、TRF水平显著低于初发血透组(P<0.05)；肾移植失功组Cr、BUN水平较初发血透组低(P<0.05),GFR较初发血透组高(P<0.01)；肾移植失功组CRP水平较初发血透组高(P<0.01)；其余指标均无显著性差异(P>0.05)。
[结论]
肾移植失功组左室重塑较初发血透组显著,其微炎症状态、贫血、营养不良程度也更显著。肾移植失功患者长期使用免疫抑制剂,加重贫血、营养不良及微炎症状态,增加肾移植患者心血管疾病的风险。肾移植患者出现肾功能不全时需要及早的干预治疗。肾移植状态存在多种因素影响患者的心脏结构和功能,因此,早期监测、预防及治疗对肾移植患者减少心血管并发症具有重要意义。
[Objective]
To study left ventricular function and its influence factors in renal transplant patients through graft loss.
[Methods]
The case group is renal transplant patients through graft loss, the control group is the patients with end-stage kidney disease but without renal transplant. Left ventricular structure and function indexs were measured by color doppler echocardiography. The blood assay indexs were determined.
[Results]
The level of IVSd, IVSs, LVPWd, LVPWs in case group were obviously higher than the control group (P<0.01);and the LVMI of the case group was higher (P<0.01); the level of Alb, Hb, Pre-Alb, TRF were obviously lower than those in control (P<0.05); The level of Cr, BUN increased in control group (P<0.05), and GFR reduced (P <0.01); The level of CRP was elevated in case group (P<0.01); The rest of the indexs had no significant difference (P>0.05).
[Conclusion]
The left ventricular remodeling of graft loss patients is significantly higher than the control group, and the micro inflammation state, anemia, malnutrition are more serious. Immune inhibitors increase micro inflammation state, anemia, and malnutrition, which increase the risk of cardiovascular disease. Early intervention treatment is needed when graft loss patients appear renal insufficiency. Various factors will influence the cardio structure and function of renal transplant patients. Therefore, early detection, prevention and treatment are important.
引文
[1]Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease[J]. Transplant 2004; 4:1662.
[2]Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease[J]. Kidney Dis 1998; 32:S112.
[3]Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986.
[4]Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.
[5]Foley RN, Parfrey PS, namett JD. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy[J]. Kidney Int 1995; 47(1): 186-192.
[6]Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure[J]. Lancet 2000; 356:147.
[7]Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease:a new paradigm[J]. Kidney Dis 2000; 35:S117.
[8]. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4:1246.
[9]. Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol 2009; 103:867.
[10]Matas AJ. Minimization of steroids in kidney transplantation[J]. Transpl Int,2009, 22(1):38-48.
[11]Molnar MZ, Novak M, Ambrus C, et al. Anemia in kidney transplanted patients[J]. Clin Transplant 2005; 19(6):825-833.
[12]Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients[J]. Transplant 2004; 4:2001.
[13]Schoming M, Eisenhandt A, Ritz E. The microinflammatory state of uremia[J]. Blood Purif; 2000; 18(4):327-332.
[14]KatoA, OdamaikM, TakitaM, et al. Creactive protein is a predictor of shout-term mortality in hemodialysis patients[J]. Nephm 2001; 21, (2):176-178.
[15]Am ann K, Wanner C, Ritz E. Cross—talk between the kidney and the cardiovascular system[J]. Soc Nephrol 2006; 17 (8):2112-2119.
[16]Ramirez R, Carracedo J, Merino A, et al. Microinflarnmation induces endothelial damage in hemodialysis patients:the role of convective transport[J]. Kidney Int 2007; 72(1):108-113.
[17]Barany P, Divino JC, Bergstrom J. High C-reactive proteinis a strong predictor of resistance to erythropoietin inhemodialysis patients[J]. Kidney Dis 2007; 29: 565-568.
[18]Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality inhemodialysis patients[J]. Kidney Dis 2006; 35: 469-476.
[19]Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients[J]. Kidney Int 2010; 77:44.
[20]Enia G, Mallam aci F, Benedetto FA, et al. Long-term CAPD pateints are volume expanded and display more severe left ventricular hypertropy than haemodialysis patients[J]. Nephrol Dial Transplant 2001; 16(7):1459-1464.
[21]Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality:an integrated point of view[J]. Am J Kidney Dis 1998; 32(5):834-841.
[22]Kalantar-Zadeh K, Stenvinkel P, Brass R, et al. Kidney insufficiency and nutrient based modulation of inflammation[J]. CurrOpinClin NutrMetab Care 2005; 8(4): 388-396.
[23]Eustace JA, Asto rB, Muntner PM, et.al Prevalence ofaeldosis and inflammation and their association wilh low serum albumin in chronic kidney disease[J]. Kidney In 2004; 65(3):1031.
[24]Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and athemsclemsisin chronic renal failure[J]. Kidney Int 1999; 55(5):1899-1911.
[25]Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population:identifying opportunities for intervention[J]. Kidney Dis 1996; 27:347.
[26]Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil[J]. Transplantation 2008; 85:1120.
[27]James W. Landmark advances in the development of erythropoietin[J]. Exp Biol Med(Maywood) 2010; 235(12):1398-1411.
[28]Kanbay M, Mark A. Perazella, Benan Kasapoglu. Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients:Review of Causes and Management[J]. Blood Purif 2010; (29):1-12.
[29]Solid CA, Foley RN, Gill JS, et al. Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants[J]. Kidney Int 2007; 71(5):425-430.
[30]Marinella MA. Hematologic abnormalities following renal transplanation[J]. Int Urol Nephrol,2009. [Epub ahead of print]
[31]Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation[J]. Kidney Dis 2004; 43:1071.
[32]Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control[J]. Transplant 2005; 5:2725.
[33]Kasiske BL, Vazquez MA, Harmon WE, et al. Recommen-dations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation[J]. Soc Nephrol 2000; 11(Suppl.15):S1.
[34]Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients[J]. Cochrane Database Syst Rev 2005; 4:CD003961.
[35]Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension[J]. N Engl J Med.2009 Aug 27;361(9):932-4.
[36]Wanic-Kossowska M. Lehmann P, Czekalski S. Left ventricular hypertrophy in patients with chronic renal failure treated by hemodialysis[J]. Pol Arch Med Wewn, 2002 Jun; 107(6):539-46.
[37]Park CW, Oh YS. Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemoclialysis patients with secondary hyperparathyroidism[J]. Am J Kidney Dis,1999 Jan; 33(1):73-81.
[38]Stefenelli T, Abela C, Frank H et al. Time course of regression of left ventficular hypertrophy after successful parathyroidectomy[J]. Surgery,1997 Feb; 121(2): 157-6.
[1]Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.
[2]Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147.
[3]Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease:a new paradigm. Am J Kidney Dis 2000; 35:S117.
[4]Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.
[5]Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008;3:491.
[6]Kidney Disease:Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl.3):S1.
[7]Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.
[8]Abedini S, Holme I, Fellstro"m B, et al. Cerebrovascular events in renal transplant recipients. Transplantation 2009;87:112.
[9]Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.
[10]Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality:The Hoorn Study. Kidney Int 2002; 62:1402.
[11]Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14:2358.
[12]Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.
[13]Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986.
[14]Shah N, Al-Khoury S, Afzali B, et al. Post-transplantation anemia in adult renal allografl recipients-prevalence and predictors[J]. Transplantation 2006; 81(8): 1112-1118.
[15]Hariharan S, McBride MA, Cherikh W S, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62:311.
[16]Opelz G, Dohler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85:661.
[17]Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62:2257.
[18]Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007; 27:498.
[19]Solez K. Vincenti F. Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine:a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66:1736.
[20]Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14:1880.
[21]Bolin P Jr, Shihab FS, Mulloy L, et al. Optimizing tacrolimus therapy in the maintenance of renal allografts:12-month results. Transplantation 2008; 86:88.
[22]Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4:CD003961.
[23]Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7:595.
[24]Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506.
[25]Boots JM, Christiaans MH, Van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients:focus on the cardiovascular risk. Drugs 2004; 64:2047.
[26]Delgado P, Diaz JM, Silva I, et al. Unmasking glucose metabolism alterations in stable renal transplant recipients:a multicenter study. Clin J Am Soc Nephrol 2008; 3: 808.
[27]Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64:979.
[28]Andrews RC, Walker BR. Glucocorticoids and insulin resistance:old hormones, new targets. Clin Sci (Lond) 1999; 96:513.
[29]Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1:1029.
[30]Boots JM, Van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus:the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13:221.
[31]Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8:307.
[32]Woodle ES. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients:one year report. Transplant Proc 2005; 37:804.
[33]Van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, Van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13:213.
[34]Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411.
[35]Araki M, Fahmy N, Zhou L, et al. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation 2006; 81:783.
[36]Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression:5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
[37]Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; ll(Suppl.15):SI.
[38]Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37.
[39]Raine AE, Carter R, Mann JI, Morris PJ. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 1988; 3:458.
[40]Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs 2001; 15:261.
[41]Derfler K, Hayde M, Heinz G, et al. Decreased post-heparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int 1991; 40:720.
[42]Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation:evidence for improved allograft survival at five years. Transplantation 2002; 73:775.
[43]Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384.
[44]Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35: 143S.
[45]Molnar MZ, Novak M, Ambrus C, et al. Anemia in kidney transplanted patientsfJ]. Clin Transplant 2005; 19(6):825-833.
[46]Am ann K, Wanner C, Ritz E. Cross—talk between the kidney and the cardiovascular system[J]. Soc Nephrol 2006; 17 (8):2112-2119.
[47]Ramirez R, Carracedo J, Merino A, et al. Microinflarnmation induces endothelial damage in hemodialysis patients:the role of convective transport[J]. Kidney Int 2007; 72(1):108-113.
[48]Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population:identifying opportunities for intervention. Am J Kidney Dis 1996; 27:347.
[49]Winkelmayer WC, Chandraker A. Pottransplantation anemia:management and rationale. Clin J Am Soc Nephrol 2008; 3(Suppl.2):S49. [50]Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85:1120.
[51]Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071.
[52]Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5:2725.
[53]Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735.
[54]Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellstrom B. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282.
[55]Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.
[56]Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as nontransplant-associated diabetes? Transplantation 1998; 65:380.
[57]Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996; 61:1469.
[58]Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin:the ALERT extension study. Am J Transplant 2005; 5:2929.
[59]Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63:331.
[60]Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection:immunologic and nonimmunologic risk factors. Kidney Int 1996; 49:518.
[61]Roodnat JI, Mulder PG, Zietse R, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69:1704.
[62]De Fijter JW, Mallat MJ, Doxiadis Ⅱ, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12:1538.
[63]Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria:causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5:2281.
[64]Halimi JM, Matthias B, Al Najjar A, et al. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 2007; 7:2775.
[65]Halimi J, Laouad I, Buchler M, et al. Early proteinuria is a strong indicator of donor renal lesions, ischemia-reperfusion injury and immunological aggression. Transplant Proc 2006; 38:2319.
[66]Prasad GV, Bandukwala F, Huang M, Zaltzman JS. Microalbuminuria post-renal transplantation:relation to cardiovascular risk factors and C-reactive protein. Clin Transplant 2009; 23:313.
[67]Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin Ⅱ type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.
[68]Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ type 1 receptor blockers:a collaborative transplant study report. J Am Soc Nephrol 2006; 17:3257.
[69]Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation:a systematic review of the evidence. Am J Transplant 2007; 7:2350.
[70]Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients:results from SECRET. Nephrol Dial Transplant 2010; 25:967.
[71]Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368.
[72]Letavernier E, Legendre C. mToR inhibitors-induced proteinuria:mechanisms, significance, and management.Transplant Rev (Orlando) 2008; 22:125.
[73]Ozdemir FN, Karakan S, Akgul A, Haberal M. Meta-bolic syndrome is related to long-term graft function in renal transplant recipients. Transplant Proc 2009; 41:2808.
[74]Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM.One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5:2922.
[75]Lentine KL, Rocca-Rey LA, Bacchi G, et al. Obesity and cardiac risk after kidney transplantation:experience at one center and comprehensive literature review. Transplantation 2008; 86:303.
[76]DeLoach SS, Joffe MM, Mai X, Goral S, Rosas SE. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 2009; 24:1314.
[77]Park CW, Oh YS. Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemoclialysis patients with secondary hyperparathyroidism[J]. Am J Kidney Dis,1999 Jan; 33(1):73-81.
[78]Stefenelli T, Abela C, Frank H et al. Time course of regression of left ventficular hypertrophy after successful parathyroidectomy[J]. Surgery,1997 Feb; 121(2):157-6.
[79]Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009:4:685.
[80]Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454.
[81]Yilmaz MI, Qureshi AR, Carrero JJ, et al. Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol 2010; 31; 214.
[82]Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT A novel marker of endothelial damage? Clin Transplant 2009; 23: 241.
[83]Paoletti E, Cannella G. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients:the potential role of mammalian target of rapamycin. Transplant Proc 2009;41:S3.
[84]Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60:908.
[85]Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12:1079.
[86]Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients:a 1-year non-randomized controlled trial. Am J Kidney Dis 2008; 52:324.
[2]Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease[J]. Kidney Dis 1998; 32:S112.
[3]Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986.
[4]Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.
[5]Foley RN, Parfrey PS, namett JD. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy[J]. Kidney Int 1995; 47(1): 186-192.
[6]Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure[J]. Lancet 2000; 356:147.
[7]Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease:a new paradigm[J]. Kidney Dis 2000; 35:S117.
[8]. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4:1246.
[9]. Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol 2009; 103:867.
[10]Matas AJ. Minimization of steroids in kidney transplantation[J]. Transpl Int,2009, 22(1):38-48.
[11]Molnar MZ, Novak M, Ambrus C, et al. Anemia in kidney transplanted patients[J]. Clin Transplant 2005; 19(6):825-833.
[12]Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients[J]. Transplant 2004; 4:2001.
[13]Schoming M, Eisenhandt A, Ritz E. The microinflammatory state of uremia[J]. Blood Purif; 2000; 18(4):327-332.
[14]KatoA, OdamaikM, TakitaM, et al. Creactive protein is a predictor of shout-term mortality in hemodialysis patients[J]. Nephm 2001; 21, (2):176-178.
[15]Am ann K, Wanner C, Ritz E. Cross—talk between the kidney and the cardiovascular system[J]. Soc Nephrol 2006; 17 (8):2112-2119.
[16]Ramirez R, Carracedo J, Merino A, et al. Microinflarnmation induces endothelial damage in hemodialysis patients:the role of convective transport[J]. Kidney Int 2007; 72(1):108-113.
[17]Barany P, Divino JC, Bergstrom J. High C-reactive proteinis a strong predictor of resistance to erythropoietin inhemodialysis patients[J]. Kidney Dis 2007; 29: 565-568.
[18]Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality inhemodialysis patients[J]. Kidney Dis 2006; 35: 469-476.
[19]Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients[J]. Kidney Int 2010; 77:44.
[20]Enia G, Mallam aci F, Benedetto FA, et al. Long-term CAPD pateints are volume expanded and display more severe left ventricular hypertropy than haemodialysis patients[J]. Nephrol Dial Transplant 2001; 16(7):1459-1464.
[21]Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality:an integrated point of view[J]. Am J Kidney Dis 1998; 32(5):834-841.
[22]Kalantar-Zadeh K, Stenvinkel P, Brass R, et al. Kidney insufficiency and nutrient based modulation of inflammation[J]. CurrOpinClin NutrMetab Care 2005; 8(4): 388-396.
[23]Eustace JA, Asto rB, Muntner PM, et.al Prevalence ofaeldosis and inflammation and their association wilh low serum albumin in chronic kidney disease[J]. Kidney In 2004; 65(3):1031.
[24]Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and athemsclemsisin chronic renal failure[J]. Kidney Int 1999; 55(5):1899-1911.
[25]Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population:identifying opportunities for intervention[J]. Kidney Dis 1996; 27:347.
[26]Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil[J]. Transplantation 2008; 85:1120.
[27]James W. Landmark advances in the development of erythropoietin[J]. Exp Biol Med(Maywood) 2010; 235(12):1398-1411.
[28]Kanbay M, Mark A. Perazella, Benan Kasapoglu. Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients:Review of Causes and Management[J]. Blood Purif 2010; (29):1-12.
[29]Solid CA, Foley RN, Gill JS, et al. Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants[J]. Kidney Int 2007; 71(5):425-430.
[30]Marinella MA. Hematologic abnormalities following renal transplanation[J]. Int Urol Nephrol,2009. [Epub ahead of print]
[31]Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation[J]. Kidney Dis 2004; 43:1071.
[32]Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control[J]. Transplant 2005; 5:2725.
[33]Kasiske BL, Vazquez MA, Harmon WE, et al. Recommen-dations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation[J]. Soc Nephrol 2000; 11(Suppl.15):S1.
[34]Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients[J]. Cochrane Database Syst Rev 2005; 4:CD003961.
[35]Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension[J]. N Engl J Med.2009 Aug 27;361(9):932-4.
[36]Wanic-Kossowska M. Lehmann P, Czekalski S. Left ventricular hypertrophy in patients with chronic renal failure treated by hemodialysis[J]. Pol Arch Med Wewn, 2002 Jun; 107(6):539-46.
[37]Park CW, Oh YS. Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemoclialysis patients with secondary hyperparathyroidism[J]. Am J Kidney Dis,1999 Jan; 33(1):73-81.
[38]Stefenelli T, Abela C, Frank H et al. Time course of regression of left ventficular hypertrophy after successful parathyroidectomy[J]. Surgery,1997 Feb; 121(2): 157-6.
[1]Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.
[2]Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147.
[3]Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease:a new paradigm. Am J Kidney Dis 2000; 35:S117.
[4]Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.
[5]Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008;3:491.
[6]Kidney Disease:Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl.3):S1.
[7]Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.
[8]Abedini S, Holme I, Fellstro"m B, et al. Cerebrovascular events in renal transplant recipients. Transplantation 2009;87:112.
[9]Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.
[10]Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality:The Hoorn Study. Kidney Int 2002; 62:1402.
[11]Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14:2358.
[12]Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.
[13]Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986.
[14]Shah N, Al-Khoury S, Afzali B, et al. Post-transplantation anemia in adult renal allografl recipients-prevalence and predictors[J]. Transplantation 2006; 81(8): 1112-1118.
[15]Hariharan S, McBride MA, Cherikh W S, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62:311.
[16]Opelz G, Dohler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85:661.
[17]Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62:2257.
[18]Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007; 27:498.
[19]Solez K. Vincenti F. Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine:a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66:1736.
[20]Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14:1880.
[21]Bolin P Jr, Shihab FS, Mulloy L, et al. Optimizing tacrolimus therapy in the maintenance of renal allografts:12-month results. Transplantation 2008; 86:88.
[22]Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4:CD003961.
[23]Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7:595.
[24]Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506.
[25]Boots JM, Christiaans MH, Van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients:focus on the cardiovascular risk. Drugs 2004; 64:2047.
[26]Delgado P, Diaz JM, Silva I, et al. Unmasking glucose metabolism alterations in stable renal transplant recipients:a multicenter study. Clin J Am Soc Nephrol 2008; 3: 808.
[27]Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64:979.
[28]Andrews RC, Walker BR. Glucocorticoids and insulin resistance:old hormones, new targets. Clin Sci (Lond) 1999; 96:513.
[29]Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1:1029.
[30]Boots JM, Van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus:the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13:221.
[31]Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8:307.
[32]Woodle ES. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients:one year report. Transplant Proc 2005; 37:804.
[33]Van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, Van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13:213.
[34]Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411.
[35]Araki M, Fahmy N, Zhou L, et al. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation 2006; 81:783.
[36]Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression:5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
[37]Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; ll(Suppl.15):SI.
[38]Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37.
[39]Raine AE, Carter R, Mann JI, Morris PJ. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 1988; 3:458.
[40]Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs 2001; 15:261.
[41]Derfler K, Hayde M, Heinz G, et al. Decreased post-heparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int 1991; 40:720.
[42]Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation:evidence for improved allograft survival at five years. Transplantation 2002; 73:775.
[43]Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384.
[44]Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35: 143S.
[45]Molnar MZ, Novak M, Ambrus C, et al. Anemia in kidney transplanted patientsfJ]. Clin Transplant 2005; 19(6):825-833.
[46]Am ann K, Wanner C, Ritz E. Cross—talk between the kidney and the cardiovascular system[J]. Soc Nephrol 2006; 17 (8):2112-2119.
[47]Ramirez R, Carracedo J, Merino A, et al. Microinflarnmation induces endothelial damage in hemodialysis patients:the role of convective transport[J]. Kidney Int 2007; 72(1):108-113.
[48]Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population:identifying opportunities for intervention. Am J Kidney Dis 1996; 27:347.
[49]Winkelmayer WC, Chandraker A. Pottransplantation anemia:management and rationale. Clin J Am Soc Nephrol 2008; 3(Suppl.2):S49. [50]Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85:1120.
[51]Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071.
[52]Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5:2725.
[53]Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735.
[54]Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellstrom B. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282.
[55]Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.
[56]Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as nontransplant-associated diabetes? Transplantation 1998; 65:380.
[57]Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996; 61:1469.
[58]Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin:the ALERT extension study. Am J Transplant 2005; 5:2929.
[59]Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63:331.
[60]Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection:immunologic and nonimmunologic risk factors. Kidney Int 1996; 49:518.
[61]Roodnat JI, Mulder PG, Zietse R, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69:1704.
[62]De Fijter JW, Mallat MJ, Doxiadis Ⅱ, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12:1538.
[63]Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria:causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5:2281.
[64]Halimi JM, Matthias B, Al Najjar A, et al. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 2007; 7:2775.
[65]Halimi J, Laouad I, Buchler M, et al. Early proteinuria is a strong indicator of donor renal lesions, ischemia-reperfusion injury and immunological aggression. Transplant Proc 2006; 38:2319.
[66]Prasad GV, Bandukwala F, Huang M, Zaltzman JS. Microalbuminuria post-renal transplantation:relation to cardiovascular risk factors and C-reactive protein. Clin Transplant 2009; 23:313.
[67]Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin Ⅱ type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.
[68]Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ type 1 receptor blockers:a collaborative transplant study report. J Am Soc Nephrol 2006; 17:3257.
[69]Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation:a systematic review of the evidence. Am J Transplant 2007; 7:2350.
[70]Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients:results from SECRET. Nephrol Dial Transplant 2010; 25:967.
[71]Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368.
[72]Letavernier E, Legendre C. mToR inhibitors-induced proteinuria:mechanisms, significance, and management.Transplant Rev (Orlando) 2008; 22:125.
[73]Ozdemir FN, Karakan S, Akgul A, Haberal M. Meta-bolic syndrome is related to long-term graft function in renal transplant recipients. Transplant Proc 2009; 41:2808.
[74]Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM.One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5:2922.
[75]Lentine KL, Rocca-Rey LA, Bacchi G, et al. Obesity and cardiac risk after kidney transplantation:experience at one center and comprehensive literature review. Transplantation 2008; 86:303.
[76]DeLoach SS, Joffe MM, Mai X, Goral S, Rosas SE. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 2009; 24:1314.
[77]Park CW, Oh YS. Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemoclialysis patients with secondary hyperparathyroidism[J]. Am J Kidney Dis,1999 Jan; 33(1):73-81.
[78]Stefenelli T, Abela C, Frank H et al. Time course of regression of left ventficular hypertrophy after successful parathyroidectomy[J]. Surgery,1997 Feb; 121(2):157-6.
[79]Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009:4:685.
[80]Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454.
[81]Yilmaz MI, Qureshi AR, Carrero JJ, et al. Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol 2010; 31; 214.
[82]Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT A novel marker of endothelial damage? Clin Transplant 2009; 23: 241.
[83]Paoletti E, Cannella G. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients:the potential role of mammalian target of rapamycin. Transplant Proc 2009;41:S3.
[84]Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60:908.
[85]Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12:1079.
[86]Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients:a 1-year non-randomized controlled trial. Am J Kidney Dis 2008; 52:324.